OTCWagon is pleased to announce we have initiated coverage on CRDL!

TORONTO - Aug. 16, 2021 - PRLog -- OTCWagon is Pleased to Announce we have started coverage on Breakout Company: Cardiol Therapeutics, Inc. (CRDL)Cardiol Therapeutics Inc. (CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular diseases.

The company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase 2/3 outcome study in hospitalized patients testing positive for COVID-19. This potentially registrational trial is designed to: (i) evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, cardiovascular disease; and (ii) investigate the influence CardiolRx has on key markers of inflammatory heart disease.

Cardiol is also planning a Phase 2 international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure, a leading cause of death and hospitalization in North America, with associated annual health care costs in the United States alone exceeding $30 billion.

OTCWagon is sure that our savvy investors will see the overwhelming value in CRDL as we do!